With a market projected to reach US$ 2,301.6 billion by 2032, the pharmaceutical manufacturing industry is not just growing—it’s evolving. The convergence of digital innovation, changing disease ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Ex-Intel head says TSMC’s new investment will not resurrect US chip sector Read the Market Summary Here:- Highlighted with 142 tables and 105 figures, this 228-page report ?Global Pharmaceutical ...

Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.